Our results suggest that reduced AR signalling may play a role in disulfiram-sunitinib co-treatment induced anti-proliferative response in prostate cancer cells since disulfiram alone had no effect on AR nor PSA expression while reduced AR and PSA levels were seen in sunitinib and disulfiram-sunitinib exposures. The gene discussed is AR; the disease is prostate carcinoma.